Showing results (2241-2250 of 3,023) with videos related to

Sort By:
Pageof 303
Leukemia & Lymphoma|August 3, 2018
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUSXiaozhong Qian, Meletios A Dimopoulos, Michael Amatangelo, et al.
Therapeutische Umschau. Revue Therapeutique|April 20, 2022
[Curative Treatment of Esophageal Carcinoma - Disease, Diagnostics, Therapy in 2022]Ulrich Klaus Fetzner, Zhanat Bekturov, Malgorzata Szczerbinska, et al.
Leukemia|May 8, 2009
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple MyelomaM Dimopoulos, E Terpos, R L Comenzo, et al.
British Journal of Cancer|November 22, 2012
VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2N G Gavalas, M Tsiatas, O Tsitsilonis, et al.
Gynecologic Oncology|March 17, 2020
Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapyMichalis Liontos, Maria Sotiropoulou, Maria Kaparelou, et al.
Frontiers in Genetics|November 5, 2019
Exome Sequencing in BRCA1- and BRCA2-Negative Greek Families Identifies MDM1 and NBEAL1 as Candidate Risk Genes for Hereditary Breast CancerStavros Glentis, Alexandros C Dimopoulos, Konstantinos Rouskas, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancerTina Bagratuni, Nefeli Mavrianou, Nikolaos G Gavalas, et al.
Future Oncology (London, England)|May 10, 2025
EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myelomaSagar Lonial, Meletios A Dimopoulos, Jesus G Berdeja, et al.
Blood|September 6, 2013
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)Meletios A Dimopoulos, Ramón García-Sanz, Maria Gavriatopoulou, et al.
Blood|March 2, 2019
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Jae Hoon Lee, Philippe Moreau, et al.
Pageof 303